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Available online 23 November 2017Objective.Microscopic residual disease following complete cytoreduction (R0) is associatedwith a significant
survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a pre-
diction model for R0 to support surgeons in their clinical care decisions.
Methods. Demographic, pathologic, surgical, and CA125 data were collected from GOG 182 records. Patients
enrolled prior to September 1, 2003 were used for the training model while those enrolled after constituted
the validation data set. Univariate analysis was performed to identify significant predictors of R0 and these var-
iables were subsequently analyzed using multivariable regression. The regression model was reduced using
backward selection and predictive accuracywas quantified using area under the receiver operating characteristic
area under the curve (AUC) in both the training and the validation data sets.
Results. Of the 3882 patients enrolled in GOG 182, 1480 had complete clinical data available for the analysis.
The training data set consisted of 1007 patients (234with R0) while the validation set was comprised of 473 pa-
tients (122 with R0). The reduced multivariable regression model demonstrated several variables predictive of
R0 at cytoreduction: Disease Score (DS) (p b 0.001), stage (p = 0.009), CA125 (p b 0.001), ascites (p b 0.001),
and stage-age interaction (p = 0.01). Applying the prediction model to the validation data resulted in an AUC
of 0.73 (0.67 to 0.78, 95% CI). Inclusion of DS enhanced the model performance to an AUC of 0.83 (0.79 to 0.88,
95% CI).
Conclusions.We developed and validated a prediction model for R0 that offers improved performance over
previously reportedmodels for prediction of residual disease. The performance of the prediction model suggests
additional factors (i.e. imaging,molecular profiling, etc.) should be explored in the future for amore clinically ac-
tionable tool.
© 2017 Elsevier Inc. All rights reserved.Keywords:
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Microscopic residual1. Introduction
Ovarian cancer is the fourth most common gynecologic malignancy
among women in the United States. By American Cancer Society esti-
mates, 22,280 women will be newly diagnosed in 2016 and 14,240
womenwill die of their disease [1]. Patientswith ovarian cancer are typ-
ically treatedwith a combination of surgical cytoreduction and adjuvant
chemotherapy. Although outcomes are adversely affected by the grade,
histology, and stage of disease, anatomical distribution of disease and
the volume of residual disease following surgical debulking may be
the strongest determinants of survival [2]. Upper abdominal surgery is
often needed to achieve maximal cytoreduction of disease and institu-
tional improvements in patient outcome have coincided from program-
matic transition to more aggressive operative intervention [3]. The
Gynecologic Oncology Group (GOG) has previously defined “optimal”
residual as b1 cm, but multiple reports now support maximum
cytoreduction to microscopic residual (R0) as being the new standard
[4–7].
The management of patients in whom R0 cannot be obtained surgi-
cally remains controversial. Some authors advocate for Neoadjuvant
Chemotherapy (NACT) with Interval Debulking Surgery (IDS) in this
scenario [8,9] while others support aggressive Primary Cytoreductive
Surgery (PDS) as long as the patients can be debulked to b1 cm of dis-
ease [10]. Some institutional studies show improved outcomes from
cytoreduction to minimal gross residual disease (NR0 b 1 cm) [10].
However, these improvements have not been reproduced using multi-
institutional data [6,7]. In a study by Horowitz et al. [11], multivariable
modeling of 2655 GOG patients with b1 cmof disease affirmed that dis-
ease distribution and disease residual, not the surgical procedure, ap-
pear to be the most important determinants of patient prognosis. In
addition, a prospective clinical trial performed by the European Organi-
zation for Research and Treatment of Cancer, investigators found that
R0 patients with NACT and IDS had a median survival of 38 months
and 28% 5-year survival compared to patients primarily debulked to
minimal gross residual disease (NR0 b 1 cm),who had amedian survival
of 32 months and a 23% 5-year survival [12]. Although no statistical
analysiswas provided, these results do not demonstrateworse outcome
for patients that receive NACT and have a higher chance for R0 at IDS
compared to patients that undergo PDS with NR0 b 1 cm. Based on
these studies [9–12], many feel that radical surgery should be reservedfor those patients that can be debulked to R0, but this is not easy to pre-
dict prior to surgery. In cases in which R0 is feasible and safe for the pa-
tient, the full range of upper abdominal and conventional cytoreductive
procedures should be deployed [13,14].
Accurate pre-operative identification of patients who are likely to
achieve R0 status at surgery could allow formore careful selection of pa-
tients for PDSwhile patientswith a low likelihood of R0 could be consid-
ered for NACT and IDS, or a minimally invasive diagnostic assessment
with laparoscopy to determine R0 feasibility. Previous attempts to de-
veloppredictionmodels of postoperative residual disease have predom-
inantly used b1 cm (instead of R0) as an endpoint for measuring
accuracy. In addition, the models developed thus far have either not
been validated in a set of patients independent from which the model
was developed or failed external validation. We sought to develop a
more robust validated model for prediction of R0 in women with ovar-
ian cancer using data from a multi-institutional cooperative group ran-
domized trial.
2. Patients and methods
All patient data were abstracted from GOG patients enrolled on the
international collaborative trial GOG-182-ICON5 [15] using existing
case report forms. Patients were enrolledwith FIGO stage III or IV histo-
logically confirmed epithelial ovarian cancer (EOC) or primary peritone-
al carcinoma (PPC). All patients underwent PDS to either ≤1 cm or
N1 cm residual disease before being randomized to one of the five plat-
inum and paclitaxel-based chemotherapy regimens. No statistically sig-
nificant treatment effects on progression-free survival (PFS) or overall
survival (OS) were found among the five chemotherapy regimens. Fur-
ther details of eligibility criteria and results from the original study have
been published [15].
Patient demographics and tumor characteristics, including age, race,
performance status, tumor grade, presence of ascites (any versus none),
and histology were extracted from the GOG database. Information de-
scribing surgical procedures and preoperative extent of disease based
on 56 anatomic locations was abstracted from GOG surgical reporting
forms and diagrams. All operative and pathology reports were evaluat-
ed to obtain accurate descriptions of disease (distribution and residual)
and surgical procedures. Preoperative CA125 was obtained from medi-
cal records submitted to the GOG as part of enrollment in GOG-182.
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used to develop the preoperative disease score (DS). The DS classes
were defined as follows: (1) DS-low, with pelvic and retroperitoneal
spread; (2) DS-moderate (DS-mod),with additional spread to the abdo-
men but sparing the upper abdomen; or (3) DS-high, with the presence
of upper abdominal disease affecting the diaphragm, spleen, liver or
pancreas. The current study included all patients with FIGO stage III or
IV EOC or PPC. The residual disease outcome was scored as completely
resected disease (R0), minimal gross residual disease (NR0 b 1 cm), or
suboptimal cytoreduction (N1 cm) followingPDS. The raw(unadjusted)
proportion of patients with R0 outcomes was estimated for each of In-
stitution in the dataset. Exploratory analysis showed considerable vari-
ability in the R0 estimates among Institutions supported by fewer
patients. The 3-level R0 stratification factor was defined at the tertiles
of R0 distribution. The R0 factor levels were low (0 to 16%), middle
(16.5 to 31%) and high (31.5 to 100%).
Model training and validation subsets were defined based on the
date of patient enrollment on the study. The patients enrolled between
February 7, 2001 andAugust 31, 2003were assigned to the training data
set while the remaining patients enrolled from September 1, 2003 to
September 1, 2004 were used for model validation. While the training
and validation patients were similar by virtue of enrollment on the
same study, this temporal allocation to training and validation sets pro-
vides a prospective assessment of model performance [16].
Using the training data, exploratory univariate analysis was per-
formed to identify predictors of R0 following PDS. Covariates for the
fullmultivariable logistic regressionmodel includedpatient characteris-
tics believed to be both available to inform the surgery decision and re-
lated to the R0 outcome. The model specification included main effects
and second-order interaction terms for age, stage, presence of ascites,
CA125 (log transformed), and GOG performance score (similar to
Karnofsky). This full model was then reduced using backward selection
constrained to respect interaction term hierarchy, with a covariate re-
tention threshold of p b 0.20. The reduction did not significantly degrade
the model fit (p= 0.7 by full and reduced model Chi square test). This
process was repeated with DS included as a covariate. To explore insti-
tutional effects on predictive accuracy, the R0 model including DS was
respecified to adjust for Institute (parent) or level R0 strata. This factor
was included as a fixed effect in the multivariable model, with themid-
dle tertile as the reference group.
R0 prediction scores for the patients in the validation data were ob-
tained using coefficient estimates from the reduced model fit to the
training data. The ability of the models to accurately distinguish be-
tween R0 vs N R0 was graphically presented with Receiver Operating
Characteristic (ROC) curves. ROC curves display the classification accu-
racy of a predictive model score as the classification threshold is varied.
For different cut-off points of themodel score, the true positive fraction
is plotted in function of the false positive fraction. The classification ac-
curacy is summarized by the area under the ROC (AUC) and its 95% con-
fidence limits. AUC values N0.80were considered to have someutility in
predicting the response of individual patients [17]. The Youden Index
[18] estimated from the training data was used to classify patients as
having either a high or low propensity for R0. This index is the basis of
other indicators of classification accuracy, including estimates for sensi-
tivity, specificity, positive and negative predictive values.
All data analyses were generated using SAS/STAT software, Version
9.4. Copyright 2012, SAS Institute Inc. SAS is a registered trademark of
SAS Institute Inc., Cary, NC, USA.
3. Results
Of the 3882 patients in the original dataset of GOG-182, 1480 had
complete preoperative data elements and were used to generate the
training cohort (n = 1007) and validation (n = 473) cohort for this
study. Although a significant number of patientswere excluded because
they did not have documentation of CA125 and ascites data (n=2215),the proportion of R0 and NR0was similar between the included and ex-
cluded cases (Supplementary Fig. 1). A total of 356 patients (24%) had
R0, 23% of the training cohort (n= 234) and 26% of the validation co-
hort (n= 122).
There were 73 parent hospitals and 240 affiliates that contributed
patients to this study. The Institutes had a median of 15 patients in
this dataset and 75% of Institutes had 30 or fewer patients. The median
R0 for the parent institution was 23% while the median R0 for affiliates
was 17%. The distribution of R0 by anonymized institution and number
of patients enrolled is shown in Supplementary Figs. 2 and 3 and Sup-
plementary Tables 1 and 2. Approximately 75% of affiliate hospitals in
our samplewere represented by b8 patients. Our samplewas not strong
enough to support hospital-level R0 estimates and so patients fromaffil-
iates were combined with patients from the parent program in provid-
ing an institution variable for modeling.
The demographics and disease characteristics for patientswith R0 vs
N R0 disease for the training cohort are presented in Tables 1 and 2.
Many of the clinical characteristics were similar between those with
R0 and NR0 residual. However, the probability of having R0 disease
was significantly associated with age, performance status, stage, extent
of disease (DS) at exploration, and presence of ascites (Table 3). Not sur-
prisingly, older, symptomatic patients with advanced stage, large vol-
ume disease, and ascites were less likely to have R0 residual. In
addition, patientswith NR0weremore likely to be olderwith symptoms
and be less ambulatory compared to patients with R0 (Table 1).
CA125 values were significantly lower for R0 (median 345 u/mL)
compared to NR0 b 1 cm (median 839 u/mL) or N1 cm (median
1241 u/mL), while the values between NR0 b 1 cm and N1 cm did not
differ significantly. Indeed, patients in all three residual disease groups
had the full range of CA125 values, making classification on the basis
of CA125 alone problematic. An exploratory analysis considered log-
transformedCA125 as a continuous predictor of the residual disease sta-
tus (R0, NR0 b 1 cm, and N1 cm). Increasing CA125 was related to in-
creasing the predicted probability of NR0 b 1 cm and N1 cm, and
decreasing probability of R0. The pattern is intuitively satisfying, and
the predicted probabilities become more compelling for CA125 value
N1000 u/mL. At this point, the predicted probably of R0 dropped to
0.18 (0.16 to 0.21), vs 0.51 (0.47 to 0.54) for NR0 b 1 cm and 0.31
(0.28 to 0.34) for N1 cm. Unfortunately, the CA125 model is least effec-
tive in lower ranges. For example, at CA125 = 35 u/mL, the predicted
probably of R0 is 0.55 (0.47 to 0.63), providing no more information
than a coin flip.
A multivariable logistic regression model to predict the probability
of R0 disease (reference: NR0) was specified to include factors believed
to be both available to inform the surgery decision and related to the R0
outcome. In preliminary analysis, non-linear effects of age and CA125
were not statistically significant, and were thus excluded. We elected
to control for institutions as a variable in ourmodelingwhichwas inclu-
sive of affiliates. Since 75% of affiliates were represented by b8 patients,
we did not use hospital as a variable in the adjusted model. The full re-
gression model was reduced by backward selection leaving age (linear)
(p b 0.001), log-transformed preoperative CA125 (linear) (p b 0.001),
DS (p b 0.001), stage (p= 0.009), presence of ascites (p b 0.001), and
the age-stage interaction term (p=0.01) as statistically significant fac-
tors. Final model specification and coefficient estimates are shown in
Table 4.
We reproduced the full and reduced multivariable regression
models including and excluding DS from the modeling. The perfor-
mance of the model exclusive of DS revealed an AUC for the model in
the training set of 0.78 (95% CI 0.74–0.81) (Fig. 1A) and in the validation
data set of 0.73 (95% CI 0.67–0.78) (Fig. 1B). Inclusion of DS in the pre-
dictionmodel resulted in an AUC 0.87 (95% CI 0.84–0.90) in the training
set (Fig. 2A) and an AUC of 0.83 (95% CI 0.79 to 0.88) in the validation
data set (Fig. 2B). An AUC of 0.87 was obtained in the validation set
when both DS and institutionwere included in the final model (Supple-
mentary Table 2 and Supplementary Fig. 4). With the DSmodel scoring
Table 1
Demographics of the Training Cohort by Residual Disease Group.
NR0 R0 Overall p value
Overall N 773 (76.8) 234 (23.2) 1007 (100%)
Age (Y) Mean/StdErr 59.5/0.4 56.2/0.7 58.7/0.3 b0.001
Median/min/max 59.4/29.5/87.5 55.7/24.5/84.7 58.9/24.5/87.5
Age (Cat) 0–54 274 (35.4%) 107 (45.7%) 381 (37.8%) 0.005
55–64 248 (32.1%) 74 (31.6%) 322 (32.0%)
65+ 251 (32.5%) 53 (22.6%) 304 (30.2%)
Race Unknown 13 (1.7%) 4 (1.7%) 17 (1.7%) 0.708
Asian 15 (1.9%) 3 (1.3%) 18 (1.8%)
Black 34 (4.4%) 7 (3.0%) 41 (4.1%)
White 711 (92.0%) 220 (94.0%) 931 (92.5%)
Ethnicity Hispanic 13 (1.7%) 4 (1.7%) 17 (1.7%) 0.682
Non-Hispanic 704 (91.1%) 209 (89.3%) 913 (90.7%)
Not known 56 (7.2%) 21 (9.0%) 77 (7.6%)
BMI Under 27 (3.5%) 8 (3.4%) 35 (3.5%) 0.412
Normal 321 (41.5%) 89 (38.0%) 410 (40.7%)
Over 213 (27.6%) 69 (29.5%) 282 (28.0%)
Obese 186 (24.1%) 54 (23.1%) 240 (23.8%)
Missing 26 (3.4%) 14 (6.0%) 40 (4.0%)
Performance Asymptomatic 320 (41.4%) 127 (54.3%) 447 (44.4%) 0.001
Ambulatory 397 (51.4%) 98 (41.9%) 495 (49.2%)
In bed b50% 56 (7.2%) 9 (3.8%) 65 (6.5%)
Performance Symptomatic 453 (58.6%) 107 (45.7%) 560 (55.6%) b0.001
Asymptomatic 320 (41.4%) 127 (54.3%) 447 (44.4%)
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sponding sensitivity and specificity of 0.80 and 0.76 respectively. Addi-
tional indicators of classification accuracy are provided in Table 5.
4. Discussion
Large numbers of patients with clinical information are required to
develop prediction models that control for multiple confounding influ-
ences. Typically, one predictor for every 10 events is recommended in
order to avoid creation of an exploratory model that does not validate
in subsequent independent testing [19,20]. Although prior models
using small numbers of patients and a regression model with multiple
variables demonstrated impressive internal prediction accuracy [21],
these initial findings were not substantiated in subsequent validation
studies in independent cohorts of patients [22,23].
Many surgeons have now adopted R0 as the most appropriate goal
for primary or interval surgery, even though clinical outcomes areTable 2
Pathologic and surgical characteristics of the Training Cohort by Residual Disease Group.
NR0 R0 Overall p value
Overall N 773 (76.8) 234 (23.2) 1007 (100%)
Site Ovary 662 (85.6%) 220 (94.0%) 882 (87.6%) b0.001
Other 111 (14.4%) 14 (6.0%) 125 (12.4%)
Histology Adeno unsp 5 (0.6%) 2 (0.9%) 7 (0.7%) b0.001
Clear cell 9 (1.2%) 19 (8.1%) 28 (2.8%)
Endomet 41 (5.3%) 28 (12.0%) 69 (6.9%)
Mucinous 7 (0.9%) 1 (0.4%) 8 (0.8%)
Mixed epi 41 (5.3%) 13 (5.6%) 54 (5.4%)
Undiffer 7 (0.9%) 4 (1.7%) 11 (1.1%)
Transition 3 (0.4%) 2 (0.9%) 5 (0.5%)
Serous 660 (85.4%) 165 (70.5%) 825 (81.9%)
Grade 1 20 (3.1%) 11 (5.6%) 31 (3.7%) 0.267
2 130 (20.1%) 40 (20.2%) 170 (20.1%)
3 497 (76.8%) 147 (74.2%) 644 (76.2%)
Stage 3 638 (82.5%) 214 (91.5%) 852 (84.6%) b0.001
4 135 (17.5%) 20 (8.5%) 155 (15.4%)
Ascites Yes 681 (88.1%) 117 (50.0%) 798 (79.2%) b0.001
No 92 (11.9%) 117 (50.0%) 209 (20.8%)
Ext of diseas DS-low 14 (1.8%) 37 (15.8%) 51 (5.1%) b0.001
DS-mod 100 (12.9%) 131 (56.0%) 231 (22.9%)
DS-high 659 (85.3%) 66 (28.2%) 725 (72.0%)
Adeno unsp - Adenocarcinoma unspecified; Endomet - Endometrioid, Epi – Epithelial;
Undiff – Undifferentiated; Transition – Transitional; Ext of Diseas – Extent of disease; DS
- Disease score; Mod - moderate.influenced by other factors, including the initial extent of disease. Our
prediction model incorporating the clinical parameters of preoperative
CA125 (linear), disease score, stage, and age-stage interaction is the
first non-surgical, validated, and reproducible predictor for disease re-
sidual and is applicable to the contemporary endpoint of R0. Such a
model and/or further refinements could complement clinical judge-
ment when considering a patient for PDS versus NACT. This model
was built on an extensive training set derived frommultiple institutions
avoiding the problem of overfitting while enhancing generalizability.
Our current model included 1007 patients, 237 of which had the resid-
ual disease endpoint (R0) thereby mitigating the effect of overfitting.
Further validation of our prediction model has shown consistency in
performance. Prior prediction models of residual disease have used
b1 cm as an endpoint for defining “optimal” residual disease [22,23,
25–28] and we have chosen R0 as the more contemporary definition
for “optimal” for the currentmodeling. Development of an accurate pre-
dictive model for achieving R0 status would have significant clinical
utility for many surgeons in making decisions about primary
cytoreduction versus NACT.
Establishment of an exploratory model and subsequent testing in an
independent validation set also should be approached with caution in
order to establish generalizability while avoiding selection bias [24]. If
one has 2 populations of patients (i.e. A and B), it is ideal to select pa-
tients from both A & B to create the prediction model and then test
the model in an independent set of patients from A & B. Development
of themodel in one population (group A) and then validation in another
population (group B) can lead to poor performance of the model in in-
dependent cohorts. In a study by Dowdy et al. [25], a prediction model
incorporating ascites and diffuse peritoneal thickening was developed
to identify 23 of 87 patients with suboptimal (N1 cm) cytoreduction
achieving 79% accuracy. Although this prediction model showed prom-
ising performance characteristics, two subsequent studies used patients
from other institutions to externally validate the model and noted that
accuracy dropped to 48% [21]–65% [23]. Similarly, the accuracy of two
predictionmodels for patientswith b1 cmof residual disease developed
by investigators from Italy [26] demonstrated a drop in AUC from 0.78
and 0.81 to 0.56–0.59 and 0.55–0.60 respectively when assessed in an
independent patient cohort by investigators in The Netherlands [27].
In the current study, patients from 73 institutions participating in
GOG-182 reflected a diversity of surgical skill levels while providing
standardization of adjuvant therapy. Our training set and validation
set of patients were similar in terms of the institutions from which
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Fig. 1. Receiver operating characteristic curves with area under the curve (AUC) and 95%
confidence interval estimates from model excluding disease distribution score, fit on the
training (A) and validation (B) data. No adjustment for Institution.
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Fig. 2. Receiver operating characteristic curves with area under the curve (AUC) and 95%
confidence interval estimates from model including disease distribution score, fit on the
training (A) and validation (B) data. No adjustments for Institution.
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model performance in validation while enhancing the generalizability
of a model that might result from single institution reporting. Consecu-
tive patients were used to create the trainingmodel and the subsequent
validation test set so that the temporal relation allowed for prospective
testing of the model thereby further enhancing its reliability [16].
Investigators from the Mayo Clinic recently published a prediction
model for R0 [29]. Although the model (including ascites, omental
thickening, and diffuse peritoneal thickening) was not externally vali-
dated using an independent sample set, investigators noted an AUC of
0.748 when internally assessing the model using a bootstrap approach
[29]. Conversely, our model for R0 was developed using a large training
set reflective of patients from multiple institutions and represents the
only externally validated model reported to date. In the validation
data, our model inclusive of DS had a AUC of 0.83 (0.79 to 0.88). Inclu-
sion of institution as a variable in the model improved the AUC further
to 0.87 in the validation dataset.
Despite its strengths, our current study has limitations. Distribution
of disease (DS) was obtained from operative notes and not pre-opera-
tive CT scans. Previous reports have highlighted the limitations of pre-operative CT scans for identification of intraperitoneal disease. In a
study by Ko et al. [30], 68 of 148 patients with stage III and IV EOC had
false negative metastasis that were not detected on initial CT but iden-
tified during surgery. Re-examination of the CT scans a second time
identified 63% of lesions that were missed on the initial examination.
Most importantly, no case was found to be false positive for metastatic
disease [30]. Although we recognize that limitations in CT detection of
metastasismight affect negative predictive value, patients unexpectedly
found to have widespread disease intraoperatively could have aggres-
sive cytoreduction postponed if radical debulking cannot render the pa-
tient R0. When we assessed the performance of the model for R0
prediction with and without inclusion of DS in the validation dataset,
we identified a substantial improvement in the AUC from 0.73 in the
model without DS to 0.83 in the model inclusive of DS in the validation
cohort. One could assume that the accuracy of the model could fall
somewhere in that range depending on the sensitivity of radiologic im-
aging in detection of disease distribution. Finally, although inclusion of
institutions improved the accuracy of the prediction model to an AUC
Table 3
Treatment and outcomes of the Training Cohort by Residual Disease Group.
NR0 R0 Overall p value
Overall N 773 (76.8) 234 (23.2) 1007 (100%)
Treatment Pac + Car 168 (21.7%) 37 (15.8%) 205 (20.4%) 0.174
Pac + Car + Gem 148 (19.1%) 46 (19.7%) 194 (19.3%)
Pac + Dox + Car 156 (20.2%) 52 (22.2%) 208 (20.7%)
Car + Top + Pac + Car 138 (17.9%) 54 (23.1%) 192 (19.1%)
Car + Gem + Pac + Car 163 (21.1%) 45 (19.2%) 208 (20.7%)
Alive/dead Alive 113 (14.6%) 91 (38.9%) 204 (20.3%) b0.001
Dead 660 (85.4%) 143 (61.1%) 803 (79.7%)
Surg aggr scr Mean/StdErr 5.0/0.1 5.2/0.2 5.0/0.1 0.262
Median/min/max 4.0/0.0/15.0 4.0/1.0/15.0 4.0/0.0/15.0
Score group CS-Low 180 (23.3%) 36 (15.4%) 216 (21.4%) 0.014
CS-Mod 465 (60.2%) 164 (70.1%) 629 (62.5%)
CS-High 128 (16.6%) 34 (14.5%) 162 (16.1%)
Surgery grp NUAP 643 (83.2%) 190 (81.2%) 833 (82.7%) 0.481
UAP 130 (16.8%) 44 (18.8%) 174 (17.3%)
Resid abstrtd Microscopic 234 (100.0%) 234 (23.2%) b0.001
Opt (b=1) 481 (62.2%) 481 (47.8%)
Sub Opt 292 (37.8%) 292 (29.0%)
Pac – Paclitaxel; Car - Carboplatin; Dox - Liposomal doxorubicin; Top - Topotecan; Gem -Gemcitabine; Dis - Disease; Surg aggr scr - Surgical aggressiveness score; CS - surgical complexity;
Grp - Group; NUAP – no upper abdominal procedures; UAP - upper abdominal surgery; Resid abstrtd – Residual disease abstracted; Opt – optimal.
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which was limited to small numbers of patients enrolled in GOG 182 at
each site. R0 rates of 100% or 0% from a few of the institutions enrolling
low numbers of patients highlight this limitation.
Given the limitations of imaging and clinical prediction of R0 at
cytoreduction, some surgeons have advocated use of diagnostic laparos-
copy to evaluate disease distribution and assess resectability. Using in-
traoperative findings at diagnostic laparoscopy to develop a risk score,
Fagotti et al. [31] developed a model to increase their rates of achieving
R0 at PDS up to 57% of patients. At a threshold score of 10, the likelihood
of R0was 0 and the risk of laparotomywas 32%. Using a predictive index
value (PIV) ≥ 8 the probability of achieving R0 at cytoreduction was
zero. The discriminating performance of this predictor for R0 revealedTable 4
Maximum likelihood coefficient estimates to predict R0 (ref: NR0) from the predictive
models using the training dataset.
Covariate Log odds estimate Standard error p value
Model excluding DS (Fig. 1A and B)
Intercept 2.55 0.64 b0.001
Log(Pre-op CA125) (continuous) −0.35 0.06 b0.001
Age (continuous) −0.03 0.01 b0.001
Ascites
Yes Reference
No 1.65 0.19 b0.001
Stage
3 Reference
4 −3.92 1.56 0.01
Age ∗ stage interaction 0.06 0.03 0.03
Model including DS (Fig. 2A and B)
Intercept 1.54 0.71 0.03
Log(Pre-op CA125) (continuous) −0.27 0.07 b0.001
Age (continuous) −0.04 0.01 b0.001
Ascites
Yes Reference
No 1.19 0.22 b0.001
Stage
3 Reference
4 −4.28 1.64 0.01
Age ∗ stage interaction 0.07 0.03 0.01
Disease score
DS-high Reference
DS-mod 2.32 0.20 b0.001
DS-low 2.53 0.37 b0.001
DS – Disease score.
Log odds estimates greater than zero indicate a greater propensity formicroscopic residual
disease after surgery, as compared to patients in the reference group, given the other co-
variates in the model.an AUC of 0.885. Several other prospective trials using laparoscopic dis-
ease assessment to triage patients are ongoing potentially allowing per-
sonalized surgical management [14,32].
Alternative to clinical or surgical parameters to predict R0
cytoreduction, molecular markers and gene expression signatures are
likely to be informative for surgical outcome. Using data from 13 public-
ly available databases Reister et al. developed and validated a gene ex-
pression signature to predict suboptimal cytoreduction [33]. Based on
protein expression of POSTN, CXCL14, and pSmad 2/3 these authors re-
port a 93% accuracy of determining a high risk and low risk group for
suboptimal cytoreduction. Perhaps combining our model with this ge-
nomic tool will provide surgeons the opportunity to triage patients ap-
propriately for primary cytoreduction or NACT.
In conclusion, ourmodel is an independently reproduciblemodel for
prediction of disease residual and is applicable to the more contempo-
rary endpoint of R0 as the goal of surgery. However, it is not meant to
be used as the sole determinant of whether a surgeon should offer a pa-
tient PDS versus NACT and IDS. Nonetheless, we hope that model will
provide surgeons with additional data to use in conjunction with the
medical condition of the patient, clinical intuition, and their patient's
preferences in deciding on a course of action.Table 5
Classification accuracy of the predictive models.
Model Accuracy Training Data Validation Data
Excluding DS
(Youden = 0.23)
AUC 0.78 (0.74 to 0.81) 0.73 (0.67 to 0.78)
Sensitivity 0.65 (0.58 to 0.70) 0.61 (0.52 to 0.69)
Specificity 0.79 (0.76 to 0.82) 0.74 (0.70 to 0.79)
PPV 0.48 (0.42 to 0.53) 0.45 (0.37 to 0.53)
NPV 0.88 (0.85 to 0.90) 0.84 (0.80 to 0.88)
Including DS
(Youden = 0.28)
AUC 0.87 (0.84 to 0.90) 0.83 (0.79 to 0.88)
Sensitivity 0.76 (0.70 to 0.81) 0.80 (0.72 to 0.86)
Specificity 0.85 (0.82 to 0.87) 0.76 (0.72 to 0.81)
PPV 0.60 (0.55 to 0.66) 0.54 (0.47 to 0.61)
NPV 0.92 (0.90 to 0.94) 0.91 (0.88 to 0.94)
DS - Disease score, AUC – area under curve, PPV - positive predictive value, NPV - negative
predictive value.
Measures of discrimination accuracy of theR0 prediction scores. Patientswere classified as
testing positive or negative using the Youden index estimated from the Training data. Ac-
curacy indicators from the Training and Validation data are shown separately. Patients
with predicted R0 probability greater or equal to the Youden indexwere classified as test-
ing positive, or having a high likelihood of R0 after surgery. PPV is the proportion of pa-
tients with a positive test who actually attained R0. NPV is the proportion of patients
with a negative test who actually failed to attain R0. Two-sided, α= 0.05 Jeffrey's confi-
dence intervals indicate reliability of the estimates.
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